AUA 2018: Safety and Efficacy of Percutaneous US and CT Guided Microwave Ablation of T1a and T1b Renal tumors

San Francisco, CA USA (UroToday.com) Sepideh Shakeri of the Department of Radiology at the University of California Los Angeles delivered a podium on their study assessing the safety and efficacy of image-guided microwave ablation (MWA) in biopsy-proven renal cell carcinoma (RCC).

To do so, they performed a retrospective review of their institutional database of patients who underwent MWA for RCC from 2013 to 2017. They abstracted data on demographics, tumor characteristics, procedural protocol, and follow-up visits within the 6-month postoperative period.

Their final analytical cohort included 70 patients with 88 biopsy-proven RCC tumors. The median (range) nephrometry score was 8 (4 - 11) and the median (range) size was 2.5 cm (0.8 – 7.4). There was no significant change in the estimated glomerular filtration rate pre- and post-ablation. The overall technical success rate was 100%. The overall complications rate was 6.8%; complications included hematoma and pain. The recurrence rate was 6.9% and occurred predominantly in those patients with clear cell RCC.

The authors concluded that ultrasound- and contrast computed tomography-guided MWA is a safe and effective treatment option with low recurrence and complication rates in those patients with T1a and T1b RCCs.

Future directions include assessing this patient cohort at a longer length of follow-up.

Presented by: Sepideh Shakeri

Written by: Michael Owyong, Department of Urology, University of California-Irvine at the 2018 AUA Annual Meeting - May 18 - 21, 2018 – San Francisco, CA USA
email news signup